Navigation Links
Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
Date:6/18/2009

LAUSANNE, Switzerland and TAMPA, Florida, June 18 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Moffitt Cancer Center (Moffitt), a non-profit Florida corporation, announce the signature of an exclusive license agreement for the development and commercialization of Debio 0928, a small molecule in early preclinical development that inhibits the protein-protein interaction between Raf-1 (key signalling kinase in the MAP kinase pathway) and Rb (retinoblastoma protein). Rb acts as a barrier to cell division and proliferation. However, when Raf-1 physically interacts with Rb, it triggers a cascade of signals that eventually overcomes this barrier, thus inducing cellular proliferation. By preventing the interaction between Raf-1 and Rb and blocking the cell cycle, Debio 0928 creates a new strategy in the fight against cancer and is thus a potentially promising novel anti-tumour drug.

Under the terms of the agreement, Debiopharm shall pay Moffitt an up-front fee, as well as predefined advanced milestone payments during the development of Debio 0928. First entry of the product into man is expected for 2012.

"This discovery, made by the collaboration between Drs. Srikumar Chellappan, Said Sebti, and Nicholas Lawrence at Moffitt, is a novel approach to the treatment of cancer," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "Being able to de-activate a key signalling kinase like Raf-1, known to be involved in many types of cancer, could open the door to more effective oncology treatments in the future."

"The disruption of the binding of the tumour promoter Raf-1 to the tumour suppressor Rb with Debio 0928 is a novel, first-in-class therapeutic strategy that has the potential for targeting a wide spectrum of human cancers," added Dr. Said Sebti, Chair, Department of Drug Discovery at Moffitt.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida, Moffitt Cancer Center [http://www.moffitt.org/] is an NCI [http://www.cancer.gov/] Comprehensive Cancer Center - a designation that recognises Moffitt's excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network [http://www.nccn.org/index.asp], a prestigious alliance of the country's leading cancer centres, and is listed in U.S. News & World Report [http://health.usnews.com/sections/health/best-hospitals] as one of "America's Best Hospitals" for cancer. Moffitt's sole mission is to contribute to the prevention and cure of cancer.

For more information on Moffitt Cancer Center, please visit: http://www.moffitt.org .

    Debiopharm S.A. Contact
    Maurice Wagner
    Director Corporate Affairs & Communication
    Tel.: +41-(0)21-321-01-11
    Fax:  +41-(0)21-321-01-69
    mwagner@debiopharm.com

    Moffitt Contact
    Michelle Foley
    Manager, Community Relations & Public Affairs
    Tel: +1-813-745-1505
    Fax: +1-813-745-1380
    michelle.foley@moffitt.org

    Additional Media Contacts
    In London
    Maitland
    Brian Hudspith
    Tel: +44-(0)20-7379-5151
    bhudspith@maitland.co.uk

    In New York
    Russo Partners, LLC
    Martina Schwarzkopf, Ph.D.
    Account Executive
    Tel: +1-212-845-4292
    Fax: +1-212-845-4260
    martina.schwarzkopf@russopartnersllc.com


'/>"/>
SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
2. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
3. Japanese Cancer Association and Debiopharm Honour Japanese Research
4. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
5. Debiopharm and EPFL Establish an Oncology Chair
6. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
7. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
8. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
9. Digital Healthcare Specialist Cadient Group Ranked #2 on List of Full-service Advertising Agencies in the Philadelphia Region
10. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
11. Cadient Group Brings Home the Gold and Two Bronze Aster Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):